Buchanan M A, Rai A, Prinsley P R
Departments of Otolaryngology, Norfolk and Norwich University Hospital, Great Yarmouth, UK.
J Laryngol Otol. 2010 Oct;124(10):1067-72. doi: 10.1017/S0022215110001118. Epub 2010 Jun 11.
To evaluate patient satisfaction and symptom improvement following treatment of Ménière's disease with the Meniett® device.
Retrospective, questionnaire-based audit and analysis of unilateral Ménière's disease patients' records, following on from a previous study from our departments on intra-tympanic gentamicin for Ménière's disease, using the Vertigo Symptom Scale and Glasgow Benefit Inventory as outcome measures.
Of 33 consecutive patients treated with the Meniett® device for four to six weeks, 30 responded to the questionnaires (90.9 per cent). Respondents' mean Vertigo Symptom Scale score was 0.7 (range 0-2.1), and their mean Glasgow Benefit Inventory general subscale score was 24.1. Nineteen (63.3 per cent) patients felt that the device had alleviated their vertigo and tinnitus.
This is the first UK study of the effectiveness of the Meniett® device in treating Ménière's disease. It shows that the Meniett® device is a well tolerated, useful and minimally invasive means of treating Ménière's disease after medical treatment has failed, and before more potentially cochleo- and vestibulo-toxic therapies and invasive procedures are utilised.
评估使用美尼埃特（Meniett®）装置治疗梅尼埃病后患者的满意度及症状改善情况。
在我们科室之前关于鼓室内注射庆大霉素治疗梅尼埃病的一项研究基础上，对单侧梅尼埃病患者的记录进行回顾性、基于问卷的审核与分析，采用眩晕症状量表和格拉斯哥获益量表作为结局指标。
连续33例使用美尼埃特（Meniett®）装置治疗4至6周的患者中，30例回复了问卷（90.9%）。回复者的眩晕症状量表平均得分为0.7（范围0 - 2.1），格拉斯哥获益量表总体子量表平均得分为24.1。19例（63.3%）患者认为该装置缓解了他们的眩晕和耳鸣。
这是英国第一项关于美尼埃特（Meniett®）装置治疗梅尼埃病有效性的研究。结果表明，在药物治疗失败后，且在采用更具潜在耳蜗和前庭毒性的疗法及侵入性手术之前，美尼埃特（Meniett®）装置是一种耐受性良好、有用且微创的梅尼埃病治疗手段。
